ATE499115T1 - Antikörper verwiesene enzymprodrugtherapie mit glukuronidase - Google Patents
Antikörper verwiesene enzymprodrugtherapie mit glukuronidaseInfo
- Publication number
- ATE499115T1 ATE499115T1 AT99948261T AT99948261T ATE499115T1 AT E499115 T1 ATE499115 T1 AT E499115T1 AT 99948261 T AT99948261 T AT 99948261T AT 99948261 T AT99948261 T AT 99948261T AT E499115 T1 ATE499115 T1 AT E499115T1
- Authority
- AT
- Austria
- Prior art keywords
- target site
- drug
- enzyme
- glucuronidase
- pretargeting
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 4
- 108090000790 Enzymes Proteins 0.000 title abstract 4
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 3
- 102000053187 Glucuronidase Human genes 0.000 title 1
- 108010060309 Glucuronidase Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 3
- 239000002254 cytotoxic agent Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 231100000419 toxicity Toxicity 0.000 abstract 2
- 230000001988 toxicity Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10103998P | 1998-09-18 | 1998-09-18 | |
| PCT/US1999/021308 WO2000016808A2 (en) | 1998-09-18 | 1999-09-17 | Antibody directed enzyme prodrug therapy (edept) with glucoronidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE499115T1 true ATE499115T1 (de) | 2011-03-15 |
Family
ID=22282805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99948261T ATE499115T1 (de) | 1998-09-18 | 1999-09-17 | Antikörper verwiesene enzymprodrugtherapie mit glukuronidase |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1113819B1 (de) |
| JP (1) | JP4616991B2 (de) |
| AT (1) | ATE499115T1 (de) |
| AU (1) | AU763628B2 (de) |
| CA (1) | CA2344440A1 (de) |
| DE (1) | DE69943219D1 (de) |
| WO (1) | WO2000016808A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833528B2 (en) | 1998-06-22 | 2010-11-16 | Immunomedics, Inc. | Use of multispecific, non-covalent complexes for targeted delivery of therapeutics |
| CA2505717A1 (en) * | 2002-11-15 | 2004-06-03 | Immunomedics, Inc. | Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics |
| JP4874090B2 (ja) * | 2003-01-31 | 2012-02-08 | イミューノメディクス、インコーポレイテッド | 治療薬および診断薬を投与するための方法および組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ225599A (en) * | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
| US5851527A (en) * | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
| DE4106389A1 (de) * | 1991-02-28 | 1992-09-03 | Behringwerke Ag | Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung |
| WO1991009134A1 (en) * | 1989-12-15 | 1991-06-27 | Takeda Chemical Industries, Ltd. | Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics |
| DE69527805T2 (de) * | 1994-12-23 | 2003-04-24 | Astrazeneca Ab, Soedertaelje | Chemische mittel |
| GB9524942D0 (en) * | 1995-12-06 | 1996-02-07 | Aepact Ltd | Drug therapy |
| ATE365562T1 (de) * | 1996-05-03 | 2007-07-15 | Immunomedics Inc | Zielgerichtete kombinations-immuntherapie für krebs |
| CN1303436A (zh) * | 1998-02-19 | 2001-07-11 | 圣朱迪儿童研究医院 | 致敏和抑制人肿瘤细胞生长的组合物和方法 |
| US7074405B1 (en) * | 1998-06-22 | 2006-07-11 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
-
1999
- 1999-09-17 EP EP99948261A patent/EP1113819B1/de not_active Expired - Lifetime
- 1999-09-17 WO PCT/US1999/021308 patent/WO2000016808A2/en not_active Ceased
- 1999-09-17 CA CA002344440A patent/CA2344440A1/en not_active Abandoned
- 1999-09-17 JP JP2000573769A patent/JP4616991B2/ja not_active Expired - Fee Related
- 1999-09-17 AT AT99948261T patent/ATE499115T1/de not_active IP Right Cessation
- 1999-09-17 DE DE69943219T patent/DE69943219D1/de not_active Expired - Lifetime
- 1999-09-17 AU AU61475/99A patent/AU763628B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002526457A (ja) | 2002-08-20 |
| AU6147599A (en) | 2000-04-10 |
| WO2000016808A3 (en) | 2000-09-28 |
| CA2344440A1 (en) | 2000-03-30 |
| DE69943219D1 (de) | 2011-04-07 |
| EP1113819A2 (de) | 2001-07-11 |
| EP1113819B1 (de) | 2011-02-23 |
| JP4616991B2 (ja) | 2011-01-19 |
| AU763628B2 (en) | 2003-07-31 |
| WO2000016808A2 (en) | 2000-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0044167A3 (de) | Durch einen Antikörper gerichtetes zytotoxisches Mittel | |
| ATE517125T1 (de) | ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN | |
| WO1994004702A3 (en) | Improved detection and therapy of lesions with biotin/avidin conjugates | |
| PT1146861E (pt) | Formulacoes de particulas de hidrogel | |
| WO2002038190A3 (en) | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | |
| ES2190075T3 (es) | Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico. | |
| BR9303469A (pt) | Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas | |
| TR199700574T1 (xx) | Molek�ler �aperon �retiminin haz�rlanmas� i�in yararl� hidroksilamin t�revleri ve bu t�revlerin haz�rlanmas�. | |
| AU7001001A (en) | Modified forms of pharmacologically active agents and uses therefor | |
| ATE81986T1 (de) | Wirkstoff - monoklonale antikoerper - konjugate. | |
| ES2102196T3 (es) | Periferializacion de celulas pluripotenciales hematopoyeticas. | |
| HUP0004348A2 (hu) | Vegyületek női szexuális diszfunkció kezelésére | |
| DE69531342D1 (de) | Avidin-biotin immunokonjugate | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| GB9415167D0 (en) | Improvements relating to cancer therapy | |
| PT615754E (pt) | Formas solidas de administracao oral de libertacao controlada flupertina | |
| BR9912975A (pt) | Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso | |
| NO944838L (no) | Arabinogalaktanderivater og anvendelser derav | |
| DK324185A (da) | 2-substituerede 1,3-propylidendiphosphonatderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf | |
| KR900007424A (ko) | 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물 | |
| AU2002216748A1 (en) | Method of treatment of seborrheic dermatitis | |
| FI891718A0 (fi) | Foerfarande foer att befria cellblandningar och vaevnader av icke-oenskade populationer. | |
| DE69943219D1 (de) | Antikörper verwiesene enzymprodrugtherapie mit glukuronidase | |
| AU8687391A (en) | Lithium treatment | |
| DE69612056D1 (de) | Terpenderivate (sarcodictyine) als antikrebsmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |